E. Roy Berger, MD, FACP
Assistant Clinical Professor, Department of Oncology, State University of New York, Stony Brook, NY.

Dr Berger is a Medical Oncologist who is recognized as a thought leader in the field of Prostate Cancer. He is one of a very small group of Medical Oncologists who has subspecialized in this disease (for over 20 years).He has written numerous articles as a result of participating in several important clinical trials that have led to the FDA approval of such drugs as Strontium and Flutamide. He was the Principal Investigator(and has the highest accruing sight in Dendreon trial D9902B) testing the dendritic cell vaccine Provenge in Hormone Refractory Prostate Cancer.

Dr. Berger has written 3 books, 2 on prostate cancer. The last one published in ' 2004.He lectures nationally to Urologists, Medical Oncologists, and patients about all aspects of the disease.

Dr. Berger serves on the Medical Advisory Boards of the 2 largest Prostate Cancer Patient Advocacy Groups in the country. He is a founding member of the Prostate Cancer Education Council, a group that has sponsored free prostate cancer screenings nationwide and increased prostate cancer awareness. He also is on multiple pharmaceutical Med. Advisory Boards and National Speaker Boards.

Dr. Berger has been a Clinical Affiliate and Consultant at Memorial Sloan-Kettering Cancer Center and and has also been cited in How to Find the Best Doctor for your Family (Castle Connolly) and Top Doctors in the New York Metro Area (Castle Connolly).

He has substantial experience presenting and consulting for financial investment firms regarding drugs being utilized for the treatment of prostate cancer.

E. David Crawford, MD
Professor of Surgery, Professor of Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center;
Associate Director of the University of Colorado Comprehensive Cancer Center, Denver, CO.

E. David Crawford, MD is the E. David and Vicki M. Crawford distinguished professor of surgery, urology, and radiation oncology, and Head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center (UCHSC) in Denver. He serves as the Senior Associate Director of the University of Colorado Comprehensive Cancer Center, also in Denver.

Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles.

Dr. Crawford is a nationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 450 articles that have been published in such journals as Urology, The New England Journal of Medicine, the Journal of Urology, and the Journal of the National Cancer Institute. He has published five textbooks and authored over 50 book chapters, and is an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology.

Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he was a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and chairs the National Prostate Cancer Education Council. His involvement in the national prostate cancer arena has been widely recognized. Dr. Crawford has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a “Freddie Award” at the AMA International Health and Medical Film Competition for the program ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Dr. Crawford hosted with special guest retired General Norman Schwarzkopf. He again won a prestigious “Freddie Award” in 2005. He has been recognized as one of the Best Doctors of America for the past decade, and Best Cancer Doctors. This year he was awarded the honor of being selected as the Best Healthcare Provider in the Denver Metro area by the Denver Business Journal, Blue Cross, and Anthem Healthcare. In 2007, was recognized as one of the top 20 urologists in the country for men by Men’s Health Magazine.

Robert Dreicer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Chairman, Department of Solid Tumors, Director of the Genitourinary Medical Oncology Program, and Associate Director of Experimental Therapeutics, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at the Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure, he was a tenured associate professor of medicine and associate division director of hematology/oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute. He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006. Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians. He is the Chair of the Steering Committee for ASCO’s 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine’s Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology.

Howard M. Sandler, MD, MS
Chair, Department of Radiation Oncology, Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

Howard Sandler, MD is currently a Newman Family Professor and Senior Associate Chair of the Department of Radiation Oncology and Professor of Urology at the University of Michigan Medical School. He obtained his medical degree and masters of science, in physics, at the University of Connecticut and was trained in radiation oncology at the University of Pennsylvania. He is the principal investigator of a national Radiation Therapy Oncology Group (RTOG 0521) protocol studying radiotherapy and chemotherapy for prostate cancer and is the principal investigator of a NIH-funded clinical trial grant investigating novel technological aspects of prostate cancer irradiation. Dr. Sandler is also the chair of the Genitourinary Cancer Committee of the RTOG. He is an active clinical trial scientist and has used an extensive prostate cancer database to study the role of radiation therapy in the treatment of prostate cancer.

A. Oliver Sartor, MD
Associate Professor of Medicine, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute; Harvard Medical School, Boston, MA.

Oliver Sartor, MD is the Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He is a medical oncologist with an interest in prostate cancer from both a basic and clinical perspective. He is on the Department of Defense Integration Panel for prostate cancer research and is the chairman-elect of the organization as well as co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Radiation Oncology Treatment Group Genitourinary Cancer Committee. In addition, Dr. Sartor is a SPORE project co-PI at Dana-Farber Cancer Center on a translational project involving the clinical outcomes and consequences of the 8q24 risk alleles. Dr. Sartor's current research interests include clinical trials in advanced prostate cancer with novel agents and novel combinations of agents. His collaborative projects include novel concepts in prostate stem cells and germ line assessment of prostate cancer risk.